For citations:
Gridneva Ya.V., Volkova M. ., Anzhiganova Yu. ., Bragina V.S., Vodolazsky V.A., Gluzman M. ., Zukov R.A., Ivanov A.M., Israelyan E.R., Karabina E.V., Kopyltsov E. ., Keln A.A., Kalpinsky A.S., Lebedinets A. ., Mochalova A.S., Novikova O.Yu., Orlova R. ., Parsadanova E.L., Petkau V.V., Pokataev I.A., Rumyantsev A.A., Safina S.Z., Stativko O.A., Sultanbaev A.V., Tovbik N. ., Shkurat A.O., Tsimafeyeu I.V. Analysis of the efficacy and safety of avelumab maintenance therapy in subgroups of patients with metastatic urothelial carcinoma in real-world practice (RAVE-Bladder Study). Malignant tumours. 2026;16(1):21-32. (In Russ.) https://doi.org/10.18027/2224-5057-2025-066
JATS XML
Email this article 